Boston Family Office LLC Purchases 8,820 Shares of Hologic, Inc. (HOLX)

Boston Family Office LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 59,965 shares of the medical equipment provider’s stock after purchasing an additional 8,820 shares during the quarter. Boston Family Office LLC’s holdings in Hologic were worth $2,564,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Koch Industries Inc. boosted its position in shares of Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 1,142,138 shares during the period. Chevy Chase Trust Holdings Inc. boosted its position in shares of Hologic by 1.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock worth $8,975,000 after buying an additional 3,391 shares during the period. Janus Henderson Group PLC boosted its position in shares of Hologic by 15.5% during the third quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock worth $10,458,000 after buying an additional 38,283 shares during the period. Cipher Capital LP boosted its position in shares of Hologic by 57.9% during the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after buying an additional 43,146 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Hologic by 66.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock worth $458,000 after buying an additional 4,984 shares during the period. 92.77% of the stock is owned by institutional investors.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $38.80 on Friday. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80. The stock has a market capitalization of $10,700.00, a PE ratio of 14.70, a P/E/G ratio of 1.89 and a beta of 0.77. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same quarter in the prior year, the company posted $0.52 earnings per share. Hologic’s revenue was up 7.7% on a year-over-year basis. analysts expect that Hologic, Inc. will post 2.18 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Cowen raised Hologic to a “buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, December 20th. Deutsche Bank cut Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Friday, January 19th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Friday, November 3rd. Finally, Goldman Sachs Group raised Hologic from a “buy” rating to a “conviction-buy” rating and upped their price objective for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $48.79.

In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2018/02/09/boston-family-office-llc-purchases-8820-shares-of-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit